Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways

Abstract

Hepatocellular carcinoma (HCC) stands as a primary malignant liver tumor characterized by chronic inflammation and complex alterations within the tumor microenvironment (TME). Lymphocyte activation gene 3 (LAG-3), also known as CD223, has gained prominence as a potential next-generation immune checkpoint, maintaining continuous expression in response to persistent antigen exposure within the TME, warranting our attention. In patients with HCC, LAG-3 expression on T cells, regulatory T cells (Tregs), and natural killer (NK) cells contributes to immune evasion, while high expression of LAG-3 leads to increased angiogenesis and poor prognosis. By interacting with major histocompatibility complex class II molecules, LAG-3 promotes T cell exhaustion and suppresses antitumor responses, often in collaboration with other immune checkpoints like programmed cell death protein 1 (PD-1), while on Tregs and NK cells, LAG-3 modulates their suppressive functions, indirectly facilitating tumor immune escape. LAG-3 expression may offer prognostic insights, correlating with disease progression and outcomes in HCC patients, while various preclinical studies highlight the potential of LAG-3-targeted therapies in reinvigorating immune responses against HCC, with a few combination approaches targeting LAG-3 alongside other checkpoints demonstrating synergistic effects in restoring T cell function. Therefore, harnessing LAG-3 as a therapeutic target holds promise for enhancing antitumor immunity and potentially improving HCC treatment outcomes. Our narrative review aims to delve into the full spectrum of LAG-3 signaling in HCC, with the goal of a better understanding of the pathophysiological and immunological basis of its use to arrest HCC growth and development.

Keywords

Lymphocyte activation gene-3 / hepatocellular carcinoma / tumor microenvironment / innate immunity / immunotherapy

References

[1] Villanueva A.Hepatocellular carcinoma.N Engl J Med2019;380:1450-62

[2] Arnold M,Neale RE.Global burden of 5 major types of gastrointestinal cancer.Gastroenterology2020;159:335-49.e15 PMCID:PMC8630546

[3] Rahib L,Aizenberg R,Fleshman JM.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res2014;74:2913-21

[4] Petrick JL,Znaor A.International trends in hepatocellular carcinoma incidence, 1978-2012.Int J Cancer2020;147:317-30 PMCID:PMC7470451

[5] Arvanitakis K,Mitroulis I.Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy.Cancers2022;14:226 PMCID:PMC8749970

[6] Arvanitakis K,Chatzigeorgiou A,Germanidis G.The liver cancer immune microenvironment: emerging concepts for myeloid cell profiling with diagnostic and therapeutic implications.Cancers2023;15:1522 PMCID:PMC10000678

[7] Arvanitakis K,Germanidis G.Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy.Cancers2021;13:2899 PMCID:PMC8228651

[8] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[9] Jinjuvadia R,Liangpunsakul S.The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis.J Clin Gastroenterol2014;48:172-7 PMCID:PMC3887366

[10] Bouvard V,Straif K.WHO International Agency for Research on Cancer Monograph Working GroupA review of human carcinogens--part B: biological agents.Lancet Oncol2009;10:321-2

[11] Ghouri YA,Rowe JH.Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis.J Carcinog2017;16:1 PMCID:PMC5490340

[12] Caruso S,Cleary SP,Zucman-Rossi J.Genetics of hepatocellular carcinoma: approaches to explore molecular diversity.Hepatology2021;73 Suppl 1:14-26

[13] Schulze K,Letouzé E.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Nat Genet2015;47:505-11 PMCID:PMC4587544

[14] Meunier L,Caruso S.DNA methylation signatures reveal the diversity of processes remodeling hepatocellular carcinoma methylomes.Hepatology2021;74:816-34

[15] De Sousa Linhares A,Grabmeier-Pfistershammer K.Not all immune checkpoints are created equal.Front Immunol2018;9:1909 PMCID:PMC6127213

[16] Sharpe AH.The diverse functions of the PD1 inhibitory pathway.Nat Rev Immunol2018;18:153-67

[17] Couzin-Frankel J.Breakthrough of the year 2013. Cancer immunotherapy.Science2013;342:1432-3

[18] Triebel F,Baixeras E.LAG-3, a novel lymphocyte activation gene closely related to CD4.J Exp Med1990;171:1393-405 PMCID:PMC2187904

[19] Wang J,Datar I.Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3.Cell2019;176:334-47.e12 PMCID:PMC6365968

[20] Lichtenegger FS,Schnorfeil FM.Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells.Front Immunol2018;9:385 PMCID:PMC5835137

[21] Ming Q,Wu C.LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.Nat Immunol2022;23:1031-41 PMCID:PMC10191176

[22] Guy C,Chou PC.LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation.Nat Immunol2022;23:757-67 PMCID:PMC9106921

[23] Huard B,Prigent P.Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.Proc Natl Acad Sci U S A1997;94:5744-9 PMCID:PMC20850

[24] Workman CJ.The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells.Eur J Immunol2003;33:970-9

[25] Annunziato F,Tomasévic I.Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production .FASEB J1996;10:769-76

[26] Workman CJ,Kim IJ,Woodland DL.Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.J Immunol2004;172:5450-5

[27] Bruniquel D,Hannier S.Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II.Immunogenetics1998;48:116-24

[28] Burton BR,Fang H.Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.Nat Commun2014;5:4741 PMCID:PMC4167604

[29] Workman C,Dugger K,Vignali D.Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).Eur J Immunol32:2255

[30] Long L,Chen F.The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy.Genes Cancer2018;9:176-89 PMCID:PMC6305110

[31] Huard B,Tournier M,Triebel F.CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins.Eur J Immunol1995;25:2718-21

[32] Liang B,Lee J.Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.J Immunol2008;180:5916-26

[33] Hemon P,Ramgolam K.MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.J Immunol2011;186:5173-83

[34] Donia M,Kjeldsen JW.Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T- Cells, which dampen CD8+ T-cell antitumor reactivity.Cancer Res2015;75:3747-59

[35] Wherry EJ,Kaech SM.Molecular signature of CD8+ T cell exhaustion during chronic viral infection.Immunity2007;27:670-84

[36] Dumic J,Flögel M.Galectin-3: an open-ended story.Biochim Biophys Acta2006;1760:616-35

[37] Kouo T,Pucsek AB.Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells.Cancer Immunol Res2015;3:412-23 PMCID:PMC4390508

[38] Liu W,Zhang G.Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node.J Biol Chem2004;279:18748-58

[39] Xu F,Liu D.LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.Cancer Res2014;74:3418-28

[40] Rimassa L,Sangro B.Combination immunotherapy for hepatocellular carcinoma.J Hepatol2023;79:506-15

[41] Kisielow M,Capoferri-Sollami G.Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.Eur J Immunol2005;35:2081-8

[42] Workman CJ.Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).J Immunol2005;174:688-95

[43] Brignone C,Marcu M,Triebel F.A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.J Immunol2007;179:4202-11

[44] Prigent P,Dréano M.Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses.Eur J Immunol1999;29:3867-76

[45] Casati C,Rini F.Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.Cancer Res2006;66:4450-60

[46] Triebel F,Pichon MF.A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.Cancer Lett2006;235:147-53

[47] Wherry EJ.T cell exhaustion.Nat Immunol2011;12:492-9

[48] Machairas N,Pawlik TM.Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma.Cancers2022;14:2018 PMCID:PMC9025403

[49] Tawbi HA,Lipson EJ.RELATIVITY-047 InvestigatorsRelatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med2022;386:24-34 PMCID:PMC9844513

[50] Paik J.Nivolumab plus relatlimab: first approval.Drugs2022;82:925-31

[51] Aggarwal V,Vignali DAA.LAG-3 as the third checkpoint inhibitor.Nat Immunol2023;24:1415-22

[52] El-Khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[53] Minaei N,Tamimi A.Immunotherapeutic approaches in Hepatocellular carcinoma: building blocks of hope in near future.Eur J Cell Biol2023;102:151284

[54] Ruff SM,Cloyd JM,Ejaz A.Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma.Curr Oncol2023;30:5863-75 PMCID:PMC10297531

[55] Hage C,Ashoff M.Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.PLoS One2019;14:e0219517 PMCID:PMC6619768

[56] Voron T,Marcheteau E.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.J Exp Med2015;212:139-48 PMCID:PMC4322048

[57] Ziogas AC,Tsiatas M.VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2.Int J Cancer2012;130:857-64

[58] Fu Z,Smaill JB,Patterson AV.Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy.Cells2021;10:1006 PMCID:PMC8146304

[59] Sarcognato S,Villanueva A.Mechanisms of action of drugs effective in hepatocellular carcinoma.Clin Liver Dis2019;14:62-5 PMCID:PMC6726381

[60] Cabrera R,Xu Y.Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.Cancer Immunol Immunother2013;62:737-46 PMCID:PMC3863727

[61] Esteban-Fabró R,Piqué-Gili M.Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma.Clin Cancer Res2022;28:2449-60 PMCID:PMC9167725

[62] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[63] Chew V,Teo M.Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.J Hepatol2010;52:370-9

[64] Foerster F,Ilyas SI.Emerging immunotherapy for HCC: a guide for hepatologists.Hepatology2022;75:1604-26 PMCID:PMC9117522

[65] Pedroza-Gonzalez A,Ijzermans JN.Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.Hepatology2013;57:183-94

[66] Nguyen LT.Clinical blockade of PD1 and LAG3--potential mechanisms of action.Nat Rev Immunol2015;15:45-56

[67] Yang C,Zhao Y.Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.Front Immunol2023;14:1112672 PMCID:PMC10040674

[68] Woo SR,Goldberg MV.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res2012;72:917-27 PMCID:PMC3288154

[69] Zhou G,Boor PPC.Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas.Gastroenterology2017;153:1107-19.e10

[70] Guo M,Qi F.Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis.J Transl Med2020;18:306 PMCID:PMC7409704

[71] Ascierto P,Bhatia S.Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations.Ann Oncol2017;28:v611-2

[72] Wang J,Tang Q.Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression.Cancer Med2020;9:7125-36 PMCID:PMC7541159

[73] Tian J,Zhang TL.Clinical significance of LAG-3 on microvessel density in primary hepatocellular carcinoma.Indian J Pathol Microbiol2022;65:581-8

[74] Cheung CCL,Fang J.Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.Front Immunol2023;14:1150985 PMCID:PMC10277502

[75] Guo M,Rao Q.Serum LAG-3 predicts outcome and treatment response in hepatocellular carcinoma patients with transarterial chemoembolization.Front Immunol2021;12:754961 PMCID:PMC8530014

[76] Yang SF,Liang JD.Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma.Cancer Lett2023;563:216192

[77] Jia J,Liu Y.Serine protease inhibitor Kazal type 1, a potential biomarker for the early detection, targeting, and prediction of response to immune checkpoint blockade therapies in hepatocellular carcinoma.Front Immunol2022;13:923031 PMCID:PMC9341429

[78] Li Y,Han Q.Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis.Mol Oncol2022;16:2861-80 PMCID:PMC9348600

[79] Macek Jilkova Z,Kurma K.Immunologic features of patients with advanced hepatocellular carcinoma before and during sorafenib or anti-programmed death-1/programmed death-l1 treatment.Clin Transl Gastroenterol2019;10:e00058 PMCID:PMC6708670

[80] Deng WW,Yu GT.LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.Oncoimmunology2016;5:e1239005 PMCID:PMC5139652

[81] Burugu S,Leung S,Nielsen TO.LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.Ann Oncol2017;28:2977-84

[82] Que Y,Guan Y.LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival.Cancer Biol Med2019;16:331-40 PMCID:PMC6713642

[83] He Y,Rozeboom L.LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes.J Thorac Oncol2017;12:814-23

[84] Zhang Y,Luo YL.Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma.J Cancer2018;9:4287-93 PMCID:PMC6277627

[85] Hald SM,Martinez I.LAG-3 in non-small-cell lung cancer: expression in primary tumors and metastatic lymph nodes is associated with improved survival.Clin Lung Cancer2018;19:249-59.e2

[86] Shepherd DJ,Kunitoki K.Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance.Mod Pathol2022;35:615-24 PMCID:PMC9050756

[87] Sangro B,Huang Y.P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073.Ann Oncol2021;32:S117

[88] Sangro B,Wadhawan S.Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.J Hepatol2020;73:1460-9 PMCID:PMC7751218

[89] Matsuzaki J,Mhawech-Fauceglia P.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Proc Natl Acad Sci U S A2010;107:7875-80 PMCID:PMC2867907

[90] Baumeister SH,Dranoff G.Coinhibitory pathways in immunotherapy for cancer.Annu Rev Immunol2016;34:539-73

[91] Bie F,Qu X.Loss of FGL1 induces epithelial-mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma.Int J Oncol2019;55:697-707

[92] Nayeb-Hashemi H,Demchev V.Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.Biochem Biophys Res Commun2015;465:167-73 PMCID:PMC4594872

[93] Wang Z,Qin X,Wu S.PI3K/AKT/mTOR pathway-associated genes reveal a putative prognostic signature correlated with immune infiltration in hepatocellular carcinoma.Dis Markers2022;2022:7545666 PMCID:PMC9112180